The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer.
 
Thomas J. Herzog
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Clovis Oncology; Johnson & Johnson; Roche/Genentech
 
Sharad A. Ghamande
Research Funding - Morphotek
 
Hani Gabra
Consulting or Advisory Role - Morphotek
Research Funding - Morphotek
 
Deborah Kay Armstrong
Consulting or Advisory Role - Eisai (I); Morphotek; Vertex
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (I); Exelixis (I)
Other Relationship - FDA
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; MSD; Pfizer
Research Funding - Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Bradley J. Monk
Consulting or Advisory Role - Advaxis; Amgen; AstraZeneca; Bayer; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Insys Therapeutics; Merck; Nucana; Oxigene; Pfizer; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Janssen; Myriad Genetics; Roche/Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Tesaro (Inst)
 
Sandro Pignata
Research Funding - Morphotek
 
Antonio Gonzalez-Martin
Research Funding - Morphotek
 
Jalid Sehouli
Consulting or Advisory Role - Morphotek
Research Funding - Morphotek
 
Charles Schweizer
Employment - Morphotek
 
Susan Weil
Employment - Morphotek
 
Kimberly Hoffman
Employment - Morphotek
 
Luigi Grasso
Employment - Morphotek
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; Gradalis; Merck; Merrimack; Millennium
 
Ignace Vergote
No Relationships to Disclose